What You Should Know:
– Fangzhou Inc., a leader in Internet healthcare solutions announced a strategic collaboration with Novo Nordisk, a leading global healthcare company.
– The Memorandum of Understanding (MOU) was signed at the 3rd…
Continue Reading
Pharma giant Novo Nordisk announced that it is collaborating with WeightWatchers to offer Wegovy through NovoCare Pharmacy, effective July 1. Through the partnership, WeightWatchers’ telehealth program, integrated into NovoCare Pharmacy, will enable new uninsured or…
Continue Reading
What You Should Know:
–DCAI today announced that Novo Nordisk has become a customer of the Gefion AI supercomputer.
– Through this agreement, Novo Nordisk will gain access to Gefion’s unparalleled computational capabilities to process vast datasets, with a…
Continue Reading
What You Should Know:
– LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide).
– The comprehensive package includes both the GLP-1 medication…
Continue Reading
Patent Monopolies Drive Record Profits
Novo Nordisk and Eli Lilly have transformed GLP-1 receptor agonists into unprecedented profit machines. These blockbuster drugs, approved for diabetes and weight loss, generate billions while leaving many patients unable…
Direct-to-consumer virtual care company Hims & Hers is partnering with Novo Nordisk to allow Americans to access a bundled offering that includes the pharma giant’s obesity drug Wegovy and a Hims & Hers membership…
Continue Reading
Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of compounded GLP-1s for patients.
Compounded GLP-1s are custom-made by compounding pharmacies and include the same…
Continue Reading
